CJC-1295 / Ipamorelin Blend Research Guide

Overview

What is the CJC-1295 / Ipamorelin Blend?

The CJC-1295/Ipamorelin blend combines Modified GRF 1-29 (CJC-1295 without DAC) with Ipamorelin in a single vial. This pairing is the most extensively studied and widely used growth hormone secretagogue combination in the research community. The rationale is synergistic: CJC-1295 (a GHRH analog) and Ipamorelin (a GHRP/ghrelin receptor agonist) stimulate GH release through two independent receptor pathways on pituitary somatotroph cells.

GHRH receptor activation by CJC-1295 increases the amplitude of GH pulses, while GHSR activation by Ipamorelin increases the frequency of GH release. When administered together, the two signals converge to produce GH output significantly greater than either compound alone, often 3–5 fold higher than single-agent administration. This synergistic amplification has been documented in both animal models and clinical pharmacology studies.

The combination is preferred over using either compound individually because it more closely mimics the natural dual-signal regulation of GH secretion. In physiological conditions, both GHRH and ghrelin (the endogenous ligand for the GHS receptor) work together to regulate GH pulsatility. The CJC-1295/Ipamorelin combination recapitulates this dual-signal model while maintaining the selectivity advantages of Ipamorelin — no significant cortisol, prolactin, or aldosterone elevation.

Science

Mechanism of Action

The CJC-1295/Ipamorelin blend achieves synergistic growth hormone release through simultaneous activation of two independent receptor systems on pituitary somatotroph cells.

CJC-1295 (Modified GRF 1-29): GHRH Receptor Agonism

CJC-1295 without DAC is a modified 29-amino acid fragment of growth hormone-releasing hormone (GHRH). It binds to the GHRH receptor (GHRHR) on pituitary somatotrophs, activating the cAMP/PKA signaling cascade. This increases the amplitude of GH pulses by directly stimulating GH gene transcription and secretory granule release. The modifications at positions 2, 8, 15, and 27 of the native GHRH sequence protect against DPP-IV enzymatic degradation, extending the active half-life from 7 minutes (native GHRH) to approximately 30 minutes [1].

Ipamorelin: Ghrelin Receptor (GHS-R) Agonism

Ipamorelin is a pentapeptide growth hormone secretagogue that binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the endogenous hunger hormone ghrelin. It stimulates GH release by increasing the frequency of GH pulses and by amplifying the somatotroph response to concurrent GHRH signaling. Ipamorelin is distinguished from other GHRPs (GHRP-2, GHRP-6, Hexarelin) by its selectivity: it does not significantly increase cortisol, prolactin, or aldosterone at standard doses, making it the cleanest GHRP available [2].

Synergistic Amplification

When GHRH and GHRP signals arrive at the somatotroph simultaneously, the GH response is multiplicative rather than additive. This synergy arises because the two pathways converge on intracellular calcium signaling through different upstream mechanisms: GHRH via cAMP/PKA-mediated calcium channel activation, and Ipamorelin via phospholipase C/IP3-mediated calcium release from intracellular stores. The combined calcium signal produces a GH secretory burst 3–5 times greater than either signal alone [3].

Pulsatile Release Preservation

A key advantage of this combination over exogenous GH administration is that it preserves the pulsatile pattern of GH release. Exogenous GH creates a flat, non-physiological GH profile that can suppress endogenous production through negative feedback. The CJC-1295/Ipamorelin combination, by contrast, stimulates the pituitary to release its own GH stores in natural pulse patterns, maintaining the integrity of the GH/IGF-1 feedback axis [4].

Dosing

Dosing Protocol

Dosing focuses on timing relative to meals and sleep. The pre-sleep dose is the most important, as it amplifies the natural nocturnal GH surge.

Protocol	Dose (each compound)	Frequency	Duration	Notes
Standard	100–200 mcg each	2–3x daily	8–12 weeks	Pre-sleep is the most important dose
Conservative	100 mcg each	2x daily (AM + PM)	8–12 weeks	Lower total daily exposure
Aggressive	200 mcg each	3x daily	8–12 weeks	Post-exercise, pre-sleep, AM fasted
Maintenance	100 mcg each	Once daily (pre-sleep)	Ongoing	Long-term low-dose approach

Dosing Notes
Must inject fasted. Carbohydrates and fats blunt the GH response significantly. Wait at least 2 hours after eating, and do not eat for 20–30 minutes after injection.
The pre-sleep dose capitalizes on the natural nocturnal GH surge — this is the single most important injection timing.
Post-exercise is the second-best timing window, as exercise primes pituitary somatotrophs for GH release.
Cycle 8–12 weeks on, 4 weeks off to prevent GHS receptor desensitization.
No need to ramp up or taper — standard doses can be used from day one.

Preparation

Reconstitution Guide

Reconstitute the lyophilized CJC-1295/Ipamorelin blend with bacteriostatic water. The peptides dissolve readily. Never shake the vial.

Remove the plastic cap from the blend vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
Draw 2 mL of bacteriostatic water into a sterile syringe. For a 5/5 mg (10 mg total) vial, this yields 2,500 mcg/mL of each peptide.
Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

5/5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg CJC-1295 + 2,500 mcg Ipamorelin per mL

100 mcg dose (of each) = 4 units (0.04 mL) on a 100-unit insulin syringe

200 mcg dose (of each) = 8 units (0.08 mL) on a 100-unit insulin syringe

Doses per vial: 50 doses at 100 mcg each, or 25 doses at 200 mcg each

Supplies Needed (12-Week Cycle at 100 mcg 2x/day)
4 vials CJC-1295/Ipamorelin blend (5/5 mg each) — 200 doses total, covers 84 days at 2x/day with margin
2 vials bacteriostatic water (30 mL each)
170 insulin syringes (29–31 gauge, 100-unit)
Alcohol prep pads

Administration

Injection Technique

The CJC-1295/Ipamorelin blend is administered via subcutaneous (SubQ) injection. Injection site does not affect efficacy — the peptides work systemically via the bloodstream to stimulate pituitary GH release.

Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper arm.
Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Timing Matters More Than Site

With GH secretagogues, injection timing relative to food and sleep is far more important than injection site selection. Always inject in a fasted state (2+ hours post-meal) and avoid eating for 20–30 minutes after injection. The pre-sleep dose should be administered at least 2 hours after your last meal. Rotate injection sites to prevent lipodystrophy, using a clock pattern around the navel for abdominal injections.

Storage

Storage & Stability

Proper storage is essential to maintain the biological activity of both peptide components. CJC-1295 is particularly sensitive to heat degradation.

Lyophilized (Powder)

2–8°C (36–46°F)

Refrigerator. Stable for 24+ months sealed.

Lyophilized (Long-term)

-20°C (-4°F)

Freezer. Extended stability beyond 2 years.

Reconstituted

2–8°C (36–46°F)

Refrigerate immediately. Use within 21 days.

Avoid

Do not freeze reconstituted solution

Protect from light. Do not leave at room temp.

Storage Tips
Keep vials upright in the back of the refrigerator (most consistent temperature).
CJC-1295 is sensitive to heat — even brief exposure to room temperature can reduce potency over time.
Never re-freeze a reconstituted vial. Discard if left at room temperature for more than 2 hours.
Label reconstituted vials with the date to track the 21-day use window.

Safety

Side Effects & Considerations

Side effects from the CJC-1295/Ipamorelin blend are generally mild and reflect the physiological effects of elevated growth hormone levels. Ipamorelin's selectivity means this combination produces fewer off-target hormonal effects than other GH secretagogue combinations.

Commonly Reported

Water retention — mild edema in the first 1–2 weeks, particularly in the hands and feet. Usually resolves with continued use as the body adapts.
Tingling or numbness in extremities — a carpal tunnel-like sensation caused by elevated GH levels. More common at higher doses.
Transient head rush or flushing immediately after injection — lasts 1–5 minutes and is harmless.
Increased appetite — milder than GHRP-6 or GHRP-2 combinations due to Ipamorelin's selectivity.
Headache during the first few days of use — typically self-resolving.
Improved sleep quality and vivid dreams — a commonly reported positive effect attributed to enhanced GH-mediated deep sleep.

Theoretical Considerations

Long-term elevated IGF-1 levels may have theoretical implications for cancer risk, though no direct evidence exists from GH secretagogue use.
Individuals with active diabetes or insulin resistance should monitor blood glucose, as GH can antagonize insulin action.
Cycling (8–12 weeks on, 4 weeks off) is recommended to prevent GHS receptor desensitization.

Important

The CJC-1295/Ipamorelin blend is classified as a research product. It is not FDA-approved for any clinical indication. All information presented here reflects published preclinical and clinical pharmacology research and should not be construed as medical advice or a treatment recommendation.

Protocols

Stacking Protocols

The CJC-1295/Ipamorelin blend is frequently combined with other peptides to achieve specific research goals beyond GH optimization alone.

CJC/Ipa + BPC-157 (Recovery + GH Stack)

Adding BPC-157 introduces localized tissue repair capability alongside the systemic GH benefits. The elevated GH and IGF-1 from CJC/Ipamorelin may amplify BPC-157's tissue repair effects, as IGF-1 is a direct mediator of tissue remodeling.

Peptide	Dose	Frequency	Duration
CJC/Ipa Blend	100 mcg each	2x daily (AM fasted + pre-sleep)	8–12 weeks
BPC-157	250 mcg	Once daily (near injury)	4–8 weeks

Lifestyle Optimization

The following factors significantly impact GH secretagogue efficacy:

Sleep: The pre-sleep dose amplifies the natural nocturnal GH surge. Poor sleep quality dramatically reduces the benefit. Prioritize 7–9 hours of uninterrupted sleep.
Exercise: Resistance training and high-intensity intervals both prime the pituitary for GH release. Post-exercise is an excellent injection window.
Fasting compliance: Eating within the 2-hour pre-injection window or 30-minute post-injection window can reduce GH output by 50% or more. Strict fasting compliance is essential.
Body composition: Higher body fat is associated with reduced GH secretory response. The combination may become more effective as body composition improves over cycles.

Researchers studying the CJC-1295/Ipamorelin blend often investigate these related compounds:

References

Literature & Citations

Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
Bowers CY. Synergistic release of growth hormone by GHRP and GHRH. J Pediatr Endocrinol. 1993;6(3-4):221-228. PubMed
Veldhuis JD, Keenan DM, Bailey JN, et al. Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies. J Clin Endocrinol Metab. 2009;94(6):2137-2143. PubMed
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed
Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PubMed
Laferrere B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PubMed
Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab. 1992;74(6):1378-1384. PubMed

CJC-1295 / Ipamorelin Blend